SERENA-6 visual patient-reported outcomes & safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.

No changes in visual acuity or ocular structure were observed.

Patient-reported visual effects occurred early (by week 2) and were reversible post-treatment.

The proportion of patients in the camizestrant+CDK4/6i and aromatase inhibitor+CDK4/6i arm reporting short-lived visual effects (<1min) ranged from 60%-67% vs 50%-69%, respectively; visual effects causing no/a low degree of bother: 78%-88% vs 50%-75%, respectively.

During treatment, visual functioning was comparable to baseline and between arms.